23 January 2020
Visiongain’s new report the Nutrigenomics Market Report 2020-2030: Forecasts by Application (Obesity, Cardiovascular Diseases, Cancer Research) plus analysis of leading companies indicates that the global nutrigenomics market will cross 1,000.0 million revenues by 2030.
The worldwide nutrigenomics market is likely to cross USD 1,000.00 million by 2030 recording a CAGR of over 10% over the forecast period. Nutrigenomics research applications for obesity and cancer emerged as market leaders in, and over the forecast period the dominance is expected to continue to grow at a substantial CAGR. Developing regional markets, including Asia Pacific, Latin America and the Middle East, are also projected to expand rapidly due to increased cases of obesity and rising geriatric population.
Noticeable progress in the fields of proteomics, computational biology, metabolic, genomics, and bioinformatics has accelerated the use of nutrigenomics globally exponentially. Nutrigenomics helps to investigate the effect of bioactive dietary elements and nutrients on gene expression as well as to study an individual's inherent risk of disease. Nutrigenomics can also influence the different parts of a food chain, such as genetic modification of crops and animal feed.
Nutrigenomics is also used in diet design and food safety evaluation. The various advances in nutrigenomics are expected to bring innovation in the field of diet and nutrition, thereby having a positive impact on the overall consumer growth. Furthermore, the support provided by regulatory bodies in numerous countries and the technological developments in the nutrigenomics market would drive the overall growth of this market.
In the years ahead, North America is expected to make a significant contribution to the international nutrigenomics market. This can be due to the release of direct distribution networks for consumer nutrigenomics, the increase of advanced diet consumption, and the implementation of the latest technologies and biotechnologies in the food industry. Therefore, the United States and Canada have a huge number of obese patients and patients with lifestyle-related disorders such as diabetes.
The use of nutrigenomics in the anti-aging field has been made possible by numerous scientific developments. In the form of supplements, numerous customized nutritional solutions are introduced to meet the body's optimal nutritional needs, which impede cell aging by forming numerous free radicals. In addition, by exploring the interaction between genetic factors and dietary patterns, nutrigenomics also offers suggestions on options for preventive treatment or measures for treating obesity through personal nutrition.
It, in effect, will continue to fuel the future growth of this regional market. The Asia Pacific nutrigenomics market is likely to see significant growth in the years ahead due to the increasing demand for healthy foods and beverages that have boosted the adoption of nutrigenomics.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.